Fulcrum Therapeutics, Inc. · NASDAQ:FULC
Fulcrum Therapeutics — AAN 2022
21 slides from Fulcrum Therapeutics's conference presentation, Apr 5, 2022
Slide 1: An Open-Label Study of Losmapimod in Subjects with FSHD1
An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1 April 5th, 2022 Joost Kools1, Nicol Voermans1, Karlien Mul1, Lucienne Ronco2, John Jiang2, Jennifer Shoskes2, Kelly Marshall2, Diego Cadavid2, Michelle
Slide 2: Disclosures
Disclosures ▪ Jennifer Shoskes is an employee of Fulcrum Therapeutics FULCRUM THERAPEUTICS 2
Slide 3: No Treatment Options for People Living With FSHD That Address Disease Progression
Currently, There Are No Treatment Options for People Living With FSHD That Address Disease Progression FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) is caused by the aberrant expression of DUX4 in skeletal muscle STOCHASTIC DUX4 EXPRESSION contributes to disease heterogeneity, asymmetry, and variabi
Slide 4: Phase 2 Studies Designed To Capture a Wide Range of FSHD Disease Progression
Phase 2 Studies were Designed To Capture a Wide Range of FSHD Disease Progression SAFETY AND TOLERABILITY PHARMACOKINETICS AND MOLECULAR PHARMACODYNAMICS FUNCTION-PATIENT STRUCTURAL REPORTED OUTCOMES FUNCTIONAL-CLINICAL OUTCOME MEASUREMENTS FULCRUM THERAPEUTICS 4
Slide 5: OLS Design
OLS Design Single Site Open Label Study Baseline Start Losmapimod 7-Day Safety Follow-Up 52-Week Open Label Losmapimod Treatment Period 28-day 8-week Wearable Extension Screening Baseline Period Losmapimod tablet 15 mg twice per day (N=14) (N=12) Period Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit
Slide 6: Baseline and Demographic Characteristics
Baseline and Demographic Characteristics Open-Label Study Losmapimod 15 mg BID (N=14) Completed 14 (100%) Discontinued* 0 All 14 subjects completed the study DEMOGRAPHICS ▪ 2 subjects declined N 14 participation in the extension Age (years) Mean (SD) 45.7 (+/- 11.61) study - Unrelated to study White
Slide 7: Losmapimod Exhibited Expected Pharmacokinetic and Target Engagement
Losmapimod Exhibited Expected Pharmacokinetic and Target Engagement in Blood and Muscle as Observed in Previous FSHD Studies ▪ Compliance was ~98.5% based on pill count Mean concentration +/- SD (ng/mL) ▪ Blood and muscle 120 Losmapimod Serum Concentration concentrations were within the 105 expected
Slide 8: DUX4-Driven Gene Expression in Muscle Biopsies
DUX4-Driven Gene Expression in Muscle Biopsies Changes from baseline were not observed in the treatment period ▪ DUX4-driven gene expression was highly variable in OLS study group DUX4-driven gene expression DUX4-driven gene expression DUX4-driven gene expression 32 DUX4-driven gene expression 32 in
Slide 9: No or Minimal Changes Observed in Quantitative MRI Assessments of Intermediate Muscles
No or Minimal Changes Observed in Quantitative MRI Assessments of Intermediate Muscles Muscle Fat Infiltration (MFI) Muscle Fat Fraction (MFF) Lean Muscle Volume (LMV) Intermediate Muscles Intermediate Muscles Intermediate Muscles 25 50 8 45 20 40 6 35 MFF (p.p.) MFI (p.p.) LMV (cL) 15 30 25 4 10 20
Slide 10: No Change Observed in Normal Appearing Muscles
No Change Observed in Normal Appearing (A) Muscles* Muscle Fat Infiltration (MFI) Muscle Fat Fraction (MFF) Lean Muscle Volume (LMV) Normal-Appearing Muscles Normal-Appearing Muscles Normal-Appearing Muscles 25 50 15 45 20 40 35 MFF (p.p.) 10 MFI (p.p.) LMV (cL) 15 30 25 10 20 15 5 5 10 5 0 0 0 Base
Slide 11: Cross-sectional Composite Values Showed Moderate to Strong Correlations to COAs at Week 52
Cross-sectional Composite Values Showed Moderate to Strong Correlations to COAs at Week 52 • Moderate and Strong Correlations Between MRI and TUG/FSHD-TUG at Week 52 (n=14) MRI Composite Statistic TUG Cross-sectional FSHD-TUG Cross-sectional* LMV (L) r (p-value) -0.89 (<0.0001)* -0.83 (0.0002)* MFF
Slide 12: Improvement or No Change Observed in Ultrasound Assessment
Improvement or No Change Observed in Ultrasound Assessment ▪ Most muscles demonstrated stability or Ultrasound Echogenicity improvement over 52 weeks Total Abdominis right ▪ Natural history studies have shown most Abdominis left Upper extr. muscles increase in echogenicity in Deltoid right FSHD pati
Slide 13: Slowing of Disease Progression and/or Improvement Observed on Multiple RWS Measures
Slowing of Disease Progression and/or Improvement was Observed on Multiple RWS Measures No Weight 500 g Weight No Weight at 52 weeks Q1 Non-Dominant Total Surface Area Q1 Dominant Non-Dominant (n=12) Q2 Non-Dominant Dominant (n=12) Q2 Dominant -0.05 0.00 0.05 Q3 Non-Dominant Worsening Improvement Q3
Slide 14: Exploratory Annualized RWS Analysis
Exploratory Annualized RWS Analysis (percent change/year) OLS Study – Annualized RWS (% change from basline /yr) UCI 5-yr longitudinal study (n=18) Quadrant With Weights Without Weights Quadrant With W/o Dom Non-Dom Dom Non-Dom Arms were averaged Q1 9.16 8.60 11.95 7.73 Q1 -7.20 -6.62 Q2 -0.28 1.34
Slide 15: Stability or Improved Muscle Strength in Dynamometry and Myometry
Stability or Improved Muscle Strength in Hand-Held Dynamometry and Quantitative Myometry ▪ Stability or improvements from baseline, in the ▪ Stability of muscle strength via quantitative bilateral strength of shoulder abductors, ankle bedframe myometry at 52 weeks dorsiflexors, and hand grip Quantit
Slide 16: Minimal Change Observed in Other Clinical Outcome Assessments Over 52 Weeks
Minimal Change Observed in Other Clinical Outcome Assessments Over 52 Weeks Average TUG Completion Time Excluding subject using crutches TUG 0.4 Change from baseline at week 52 (sec) 0.3 0.2 0.1 Worsening 0.0 Mean + SE Losmapimod (n=11) Minimal or No Change in FSHD-TUG, FSHD-RODS, Motor Function Mea
Slide 17: Participants Reported Improvement with Losmapimod Treatment Over Time
Participants Reported Improvement with Losmapimod Treatment Over Time ▪ Over 80% of subjects reported improvement or no change after 52 weeks of treatment; no patients reported feeling much worse over 52 weeks Patients’ Global Impression of Change PGIC Score by Week (PGIC) evaluates the impression o
Slide 18: Losmapimod Was Generally Well Tolerated
Losmapimod Was Generally Well Tolerated ▪ No SAEs or deaths were observed ▪ The most common AE was increased ALT (35.7%), of which all cases were mild and transient ▪ All cases resolved with continued dosing, and none led to treatment discontinuation ▪ Nine subjects (64.3%) reported events in the SO
Slide 19: Totality of Evidence Supports Losmapimod as Potential Disease-Modifying Treatment for FSHD
The Totality of Evidence Supports Losmapimod as a Potential, Transformative Disease-Modifying Treatment for FSHD SAFETY AND TOLERABILITY DATASET PHARMACOKINETICS AND MOLECULAR >3600 subjects treated PHARMACODYNAMICS In vitro and in vivo data Extensive evaluations in patients Losmapimod for FSHD FUNC
Slide 20: Acknowledgements
Acknowledgements People Living With FSHD Participating in This Study OLS Site Collaborating Organizations Patient Groups OLS Physical Therapists OLS Study Coordinators Clinical and Scientific Advisors ▪ Baziel van Engelen, MD, PhD Radboud UMC ▪ Jeffrey Statland, MD. KUMC ▪ Lee Sweeney, PhD. UFL ▪ Le
Slide 21: Thank you! Questions?
Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge, MA, USA 02139 [email protected] Thank you! Questions? FULCRUM THERAPEUTICS 21